cd30 car-t cell

Cell therapyexperimental

Clinical trial activity

7 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2020 (NCT04268706)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06617286Phase 1/Phase 2 (Phase 2)Dec 1, 2024New York Medical College, University of North Carolina at Chapel Hill
NCT05352828Phase 1Jul 25, 2022Baylor University, Bristol-Myers Squibb, Tessa Therapeutics, University of Texas at Houston
NCT05208853Early Phase 1 (Phase 1)Feb 10, 2022Government of China, Zhejiang University
NCT05320081Phase 2Nov 30, 2021Huazhong University of Science and Technology, Nanchang University
NCT04526834Phase 1Nov 30, 2020Tessa Therapeutics, University of Texas at Houston
NCT04653649Phase 1/Phase 2 (Phase 2)Sep 29, 2020Josep Carreras Leukaemia Research Institute, Universidad Carlos III Madrid, University of Barcelona
NCT04268706Phase 2May 1, 2020Baylor University, Tessa Therapeutics
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tessa TherapeuticsFor profit3322020
Baylor UniversityAcademic/Hospital2022020
University of Texas at HoustonAcademic/Hospital2012020
Bristol-Myers SquibbFor profit1012022
Government of ChinaGovernment1012022
Huazhong University of Science and TechnologyAcademic/Hospital1112021
Josep Carreras Leukaemia Research InstituteAcademic/Hospital1012020
Nanchang UniversityAcademic/Hospital1012021
New York Medical CollegeAcademic/Hospital1112024
Universidad Carlos III MadridAcademic/Hospital1012020
University of BarcelonaAcademic/Hospital1112020
University of North Carolina at Chapel HillAcademic/Hospital1012024
Zhejiang UniversityAcademic/Hospital1112022
13 organizations
Page 1 / 1